CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Onabotulinum Toxin A for Spasticity Associated with Multiple Sclerosis

Last updated: March 11, 2021
Project Number: RC1340-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What is the clinical effectiveness of onabotulinum toxin A (Botox) in the treatment of spasticity associated with multiple sclerosis?
  2. What is the cost-effectiveness of onabotulinum toxin A (Botox) in the treatment of spasticity associated with multiple sclerosis?
  3. What are the evidence-based guidelines for the use of onabotulinum toxin A (Botox) in a treatment regimen for spasticity associated with multiple sclerosis?

Key Message

Evidence-based clinical practice guidelines recommend the use of botulinum toxin (which includes onabotulinum toxin A [Botox]) to treat spasticity caused by multiple sclerosis. There is a lack of recent evidence regarding the clinical and cost-effectiveness of Botox as a treatment for spasticity caused by multiple sclerosis; thus, there is a need for well-designed studies on this topic.